StockData
Gossamer Bio, Inc. logo

Gossamer Bio, Inc. (GOSS) stock

GOSSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 1/30
$11.43+0.39 (+3.53%)

Close on Nov 18, 2026Market cap $5.59BP/E –Yield –

Gossamer Bio total assets

Total assets on the balance sheet at the end of each period.

Gossamer Bio's total assets was $76.87M at Jun 30, 2026. For fiscal 2025 it was $172.25M, down 45.4% from the year before. The highest annual figure on record is $539.43M in fiscal 2020.

Annual total assets

PeriodPeriod endValueChange
FY2025Dec 31, 2025$172.25M-45.4%
FY2024Dec 31, 2024$315.29M+1.1%
FY2023Dec 31, 2023$311.92M+14.5%
FY2022Dec 31, 2022$272.45M-20.7%
FY2021Dec 31, 2021$343.66M-36.3%
FY2020Dec 31, 2020$539.43M+26.4%
FY2019Dec 31, 2019$426.60M+78.2%
FY2018Dec 31, 2018$239.42M–

Quarterly total assets

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$76.87M-68.1%
Q1 FY2026Mar 31, 2026$128.90M-54.1%
Q4 FY2025Dec 31, 2025$172.25M-45.4%
Q3 FY2025Sep 30, 2025$208.82M-40.5%
Q2 FY2025Jun 30, 2025$240.93M-35.5%
Q1 FY2025Mar 31, 2025$280.59M+8.2%
Q4 FY2024Dec 31, 2024$315.29M+1.1%
Q3 FY2024Sep 30, 2024$350.88M+0.8%
Q2 FY2024Jun 30, 2024$373.45M+105.5%
Q1 FY2024Mar 31, 2024$259.36M+17.9%
Q4 FY2023Dec 31, 2023$311.92M+14.5%
Q3 FY2023Sep 30, 2023$347.93M+7.5%
Q2 FY2023Jun 30, 2023$181.75M-26.1%
Q1 FY2023Mar 31, 2023$219.91M-25.4%
Q4 FY2022Dec 31, 2022$272.45M-20.7%
Q3 FY2022Sep 30, 2022$323.54M-16.4%
Q2 FY2022Jun 30, 2022$245.84M-43.2%
Q1 FY2022Mar 31, 2022$294.68M-38.9%
Q4 FY2021Dec 31, 2021$343.66M-36.3%
Q3 FY2021Sep 30, 2021$387.04M-33.7%
Q2 FY2021Jun 30, 2021$432.51M-30.8%
Q1 FY2021Mar 31, 2021$482.47M+29.9%
Q4 FY2020Dec 31, 2020$539.43M+26.4%
Q3 FY2020Sep 30, 2020$584.18M+24.4%
Q2 FY2020Jun 30, 2020$625.08M+23.2%
Q1 FY2020Mar 31, 2020$371.48M-28.0%
Q4 FY2019Dec 31, 2019$426.60M+78.2%
Q3 FY2019Sep 30, 2019$469.75M–
Q2 FY2019Jun 30, 2019$507.17M–
Q1 FY2019Mar 31, 2019$515.95M–
Q4 FY2018Dec 31, 2018$239.42M–

More Gossamer Bio figures

See a number that looks wrong?